Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Lower-Extremity Amputation: Evolving Questions, Evolving Answers

BACKGROUND: Canagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), was associated with an approximately two-fold increase in amputation risk in a recent cardiovascular outcome trial. Observational studies in real-world data have yielded mixed or inconclusive results. METHODS: We conduct...

全面介紹

Na minha lista:
書目詳細資料
發表在:Diabetes Obes Metab
Main Authors: Yang, Jeff Y., Wang, Tiansheng, Pate, Virginia, Gower, Emily W., Crowley, Matthew J., Buse, John B., Stürmer, Til
格式: Artigo
語言:Inglês
出版: 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459697/
https://ncbi.nlm.nih.gov/pubmed/30697897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13647
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍